to BioTechniques free email alert service to receive content updates.

TissueScan Oncology Panel
Sponsored,vendor-submitted protocol   Published in December 2006 2007 (p.13)


TissueScan is a unique RT-PCR based system for fast and accurate gene expression profiling across a large number of cancer patient samples. High-quality cDNAs were prepared from 48 well-documented cancer biopsy samples, normalized and assembled into ready-to-use gene expression panels. This alleviates for researchers the tedious work of large sample collection and the meticulous work of RNA/cDNA preparation, while facilitating quick and reliable profiling of gene expression levels across cancer progression stages. TissueScan combines the high sensitivity and specificity of the RT-PCR methodology with a well-designed multi-sample format. It is an excellent tool for validation of potential cancer markers such as those obtained by microarray or differential display.

TissueScan technology was developed to meet the unmet need for quick target validation in cancer biomarker field. TissueScan Oncology products are panels of cDNAs from well-documented biopsy samples. These panels currently represent 4 major types of cancers: lung cancer, colon cancer, ovarian cancer and thyroid cancer. Each sample included in the panels was obtained with the patient's consent and is accompanied by a detailed pathology report. For each cancer panel, 48 tissues were used to produce high-quality cDNA. The samples were designed to represent all progression stages, from stage 0 (pathologically normal appearing tissue) to stage IV. The cDNAs were normalized by beta-actin levels and assembled into a single, 48-well plate. Researchers can simply run a real-time PCR assay by adding PCR master mix and a pair of primers specific for the gene of interest. In mere two hours, you can obtain an accurate expression profile of any gene across 48 tissues of a particular cancer type.

Application example:

To illustrate the validity of TissueScan, we used Lung Cancer Panel (HLRT-101) to evaluate the expression level of Topoisomerase II alpha, which has been known to be upregulated in a large percentage of lung cancers. A pair of primers was designed to detect the transcript of this gene. SYBR Green I based real-time PCR was performed. The raw data (Figure A) and the expression level plot calculated by the Ct method (Figure B) are shown below. A second panel in the kit was used with beta-actin control primers provided in the kit (Figure C).

The results showed that TOPOII expression levels are markedly higher than in the normal tissues, supporting the notion that topoisomerase can serve as a valid biomarker for lung cancer.

Product offering:

TissueScan kit includes two identical 48-well panels, beta-actin control primers and a copy of the Application Guide. The normalized cDNAs are lyophilized in 48-well PCR plates.

HCRT101: Colon Cancer Panel

HLTR101: Lung Cancer Panel

HCRT101: Colon Cancer Panel

HLTR101: Lung Cancer Panel

For more information, call 1-888-267-4436 or visit Web site (external)

More Information
Do you have question about this protocol? Would you like more information about this protocol?
Submit your questions here and Biotechniques will forward your question and contact information from our database to an expert at
Yes, please forward my question, along with my name, title, company, and e-mail address to
BioTechniques will forward your question to the company, who will contact you directly by email.
Request more information
Name Question
Job Title
rightcontent.jsp called otherwise condition rightcontent.jsp called 222222222222222222222
Search Protocols
Search our protocols for your specific technique.
Submit Your Protocols
BioTechniques is always looking for author-submitted protocols related to peer-reviewed papers, so submit your protocols today to our editorial team. Suppliers or advertisers interested in publishing their protocols should also submit.
Click here for more information